Literature DB >> 31709040

When Theory Becomes Reality: Navigating the Ethics of Transplanting Hepatitis C Virus-Positive Livers Into Negative Recipients.

Thomas Couri1, Andrew Aronsohn2.   

Abstract

Entities:  

Year:  2019        PMID： 31709040      PMCID： PMC6832093          DOI： 10.1002/cld.849

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  27 in total

1.  Utilization of hepatitis C virus RNA-positive donor liver for transplant to hepatitis C virus RNA-negative recipient.

Authors:  Behnam Saberi; James P Hamilton; Christine M Durand; Zhiping Li; Benjamin Philosophe; Andrew M Cameron; Mark S Sulkowski; Ahmet Gurakar
Journal:  Liver Transpl       Date:  2018-01       Impact factor: 5.799

2.  Provider utilization of high-risk donor organs and nucleic acid testing: results of two national surveys.

Authors:  L M Kucirka; R Namuyinga; C Hanrahan; R A Montgomery; D L Segev
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

3.  Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago.

Authors:  Thomas Couri; Thomas G Cotter; Daniel Chen; Mary Hammes; Bharathi Reddy; Michelle Josephson; Heidi Yeh; Raymond T Chung; Sonali Paul
Journal:  Am J Nephrol       Date:  2018-12-14       Impact factor: 3.754

Review 4.  Medical ethics: four principles plus attention to scope.

Authors:  R Gillon
Journal:  BMJ       Date:  1994-07-16

Review 5.  Liver transplantation and hepatitis C.

Authors:  A Rubín; V Aguilera; M Berenguer
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-10-01       Impact factor: 2.947

6.  Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation.

Authors:  John F Renz; Cindy Kin; Milan Kinkhabwala; Dominique Jan; Rhaghu Varadarajan; Michael Goldstein; Robert Brown; Jean C Emond
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

7.  Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management.

Authors:  S Huprikar; L Danziger-Isakov; J Ahn; S Naugler; E Blumberg; R K Avery; C Koval; E D Lease; A Pillai; K E Doucette; J Levitsky; M I Morris; K Lu; J K McDermott; T Mone; J P Orlowski; D M Dadhania; K Abbott; S Horslen; B L Laskin; A Mougdil; V L Venkat; K Korenblat; V Kumar; P Grossi; R D Bloom; K Brown; C N Kotton; D Kumar
Journal:  Am J Transplant       Date:  2015-02-23       Impact factor: 8.086

8.  Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy.

Authors:  Gaurav Gupta; Yiran Zhang; Norman V Carroll; Richard K Sterling
Journal:  Am J Transplant       Date:  2018-08-30       Impact factor: 8.086

9.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

10.  Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.

Authors:  Paul Kwo; Norman Gitlin; Ronald Nahass; David Bernstein; Kyle Etzkorn; Sergio Rojter; Eugene Schiff; Mitchell Davis; Peter Ruane; Ziad Younes; Ronald Kalmeijer; Rekha Sinha; Monika Peeters; Oliver Lenz; Bart Fevery; Guy De La Rosa; Jane Scott; James Witek
Journal:  Hepatology       Date:  2016-03-22       Impact factor: 17.425
View more
  1 in total

Review 1.  Transplantation of Organs from Hepatitis C Virus-Positive Donors under Direct-Acting Antiviral Regimens.

Authors:  Muhammad Nauman Zahid
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.